• Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection

  NCT01019889

  CompletedInterventionalPhase 3Updated Apr 6, 2012
• Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo)

  NCT00065715

  CompletedInterventionalPhase 3Updated Dec 4, 2014
• Efficacy and Safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean Patients With Cold Hypersensitivity in the Hands

  NCT02645916

  CompletedInterventionalPhase 4Updated Nov 29, 2017
• Efficacy of an Extract of Concentrated Korean Red Ginseng for Preventing Upper Respiratory Tract Infections

  NCT01478009

  CompletedInterventionalPhase 2Phase 3Updated Dec 25, 2012
• Efficacy and Safety of Ucha-Shinki-Hwan on Korean Patients With Cold Hypersensitivity in the Hands and Feet-Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial

  NCT03790033

  CompletedInterventionalPhase 2Phase 3Updated Sep 1, 2021
• Safety and Intake Effect of EPs® 7630 (an Extract of the Roots of Pelargonium Sidoides)

  NCT02174653

  CompletedInterventionalPhase 3Updated Jan 12, 2017

ClinicalTrials.gov ID

NCT04073511

Lead Sponsor

Korean Medicine Hospital of Pusan National UniversityOTHER

Overall Status

Unknown status

Study Type

Interventional

Phase

Not Applicable

Enrollment

375Estimated

Last Update Posted

Sep 3, 2019Actual

Start Date

Sep 16, 2019Estimated

Primary Completion Date

Dec 27, 2020Estimated

Completion Date

Dec 31, 2020Estimated

Official Title

The Effectiveness and Safety of 'Eungyosan' and 'Samsoeum' for Common Cold - a Randomized, Parallel-group, Placebo-controlled, Multicenter Clinical Trial

Brief Summary

The investigators intend to conduct a multicenter clinical trial to verify the effectiveness and safety of the administration of 'Eungyosan(EGS)' and 'Samsoeum(SSE)' in cold patients.

Detailed Description

375 participants with symptoms of the common cold within 48 h will be recruited for this randomized, placebo-controlled trial. Subjects who will participate in the study will be divided into three groups, 'Eungyosan' group(EGS), 'Samsoeum' group(SSE) and placebo group according to the randomization number. Each group of subjects will take the drugs(EGS or SSE or placebo) 3 times a day up to 8 days.

The severity of illness will be assessed by Wisconsin Upper Respiratory Symptom Survey-21 Korean version (WURSS-21-K) and the VAS(visual analog scale) every 8days. Also, the duration of the common cold will be checked to evaluate the effectiveness.

• Common Cold

• Eungyosan
• Samsoeum
• Placebo

Ages Eligible for Study

Adult (18-64)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Male and female aged between 19 and 60 years as of the screening date
2. Onset of cold symptoms within 48 hours before screening
3. Those who have one or more of the symptoms and related symptoms of runny nose and sore throat (Related symptoms: nasal congestion, sneezing, sore throat, cough, sore throat, headache, chest tightness, fatigue)
4. Those who demonstrate understanding of the study details and have willingness to participate as evidenced by voluntary written informed consent
5. Those who can be followed up during the clinical trial
6. Those who do not meet the exclusion criteria

Exclusion Criteria:

1. Those who have sinusitis (when the sinus is opaque at the time of examination through the transillumination of the maxillary sinus and the frontal sinus), allergic rhinitis, pneumonia, flu (when coughing or sore throat with sudden fever above 38 ℃), bronchitis, otitis media, tonsillitis (PNS view, Chest Xray test if accurate test is needed)
2. Those who have chronic respiratory disease (chronic obstructive pulmonary disease, interstitial lung disease) and asthma
3. Those who have taken or should be taking or are taking antibiotics, antivirals, steroids, nasal decongestants, antihistamines, or other medications that are expected to alleviate cold symptoms, or those who have taken food that is expected to relieve cold symptoms within one week of the start of the study
4. Those who are being treated for liver cancer or cirrhosis, chronic renal failure, congestive heart failure, etc.
5. Those who have systemic disease or autoimmune disease which does not affect cold symptoms
6. Those who have severe mental illnesses such as depression or anxiety disorders, or those who are currently taking psychoneurological drugs such as antidepressants
7. Drug addicts or alcoholics
8. Alanine transaminase (ALT) or aspartate transaminase (AST) exceeds 3 times the upper limit of normal
9. Creatinine exceeds twice the upper limit of normal of the research institute
10. Weak person (less than body weight index (BMI) 18.5, clinically judged by Korean medical doctor through physical examination)
11. Those who have a weak stomach and are considered to be inadequate to take investigational drug (clinically judged by Korean medical doctor through physical examination)
12. Those who are with high blood pressure (vital sign measured at upper left after resting for at least 5 minutes at screening: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥ 100 mmHg) or elderly
13. Those who have cardiac disorder or renal disorder (clinically judged by Korean medical doctor through physical examination, ECG, and serum biochemistry)
14. Those who have histories of hives, rash, or itching while taking medicines
15. Participants in other clinical trials within one month of the start of the trial (30 days prior to the screening visit) or plan to participate in other clinical trials during the trial
16. Pregnant women or women who may be pregnant
17. Those who do not agree to contraception in case of women of childbearing age
18. Those who are being held in group facilities such as social welfare facilities
19. Those who are inappropriate to participate in the trial by the investigator's judgment
20. Those who have hypersensitivity to the investigational drug (main ingredient and its components)
21. Those who have genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
22. Those who have hypokalemia
23. Those who have difficulty in daily life due to sweats (excessive sweating, general weakness, etc.)
24. Those who have difficulty in daily life due to anorexia, nausea or vomiting
25. Those who are suspected of having pneumonia and need antibiotic treatment or those who are receiving medical treatment (those receiving other medications)

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Triple

Lead Sponsor

Korean Medicine Hospital of Pusan National UniversityOTHER

franchisjun@naver.com